FIELD: medicine.
SUBSTANCE: invention refers to medicine, namely to experimental medicine and oncology, and can be used for combined therapy of liver cancer PC-1 in experiment. Method involves the daily introduction of cyclophosphamide in dose of 5 mg/kg for 3 weeks. Not earlier than 30 minutes later and not later than 45 minutes from the administration of cyclophosphamide, intraperitoneal introduction of a solution of gratiole extract daily in dose of 110 mg/kg.
EFFECT: use of the invention enables to potentiate anticancer effects of said substances in 2_6 times compared to separate use of cyclophosphamide, as well as a favorable effect on the body of laboratory animals with tumor, promotes body weight gain, prevents development of cachexia due to reduced toxicity by gratiole extract used in combination of cyclophosphamide, and reduced toxic effect of disintegration and tumor necrosis.
1 cl, 1 ex, 5 dwg
Title | Year | Author | Number |
---|---|---|---|
AGENT POSSESSING ANTINEOPLASTIC AND IMMUNOMODULATORY ACTION | 2013 |
|
RU2519769C1 |
AGENT CAUSING IN VIVO EXPERIMENTS IN SUBSTITUTION OF TUMOR CONNECTIVE TISSUE AND TRANSFERRING TUMOR CELLS FROM G1 PHASE OF CELL CYCLE INTO REST STATE G0 | 2018 |
|
RU2731105C2 |
PRODUCT FOR TREATMENT OF TUMOR CACHEXIA | 2015 |
|
RU2578440C1 |
AGENT HAVING SELECTIVE ACTION ON TUMOR CELLS, ACTIVATING APOPTOSIS THEREOF AND PREVENTING FORMATION OF RESISTANCE THEREOF | 2018 |
|
RU2694547C1 |
COMBINATION OF DEHYDROXYMETHYL EPOXYQUINOMYCIN (DHMEQ) AND CYTOSTATICS FOR TREATING OVARIAN CANCER | 2018 |
|
RU2704020C1 |
PEPTIDE, POSSESSING ANTI-TUMOR AND ANTI-METASTATIC ACTIVITY, AND FINISHED DOSAGE FORM BASED THEREON | 2018 |
|
RU2682039C1 |
AGENT POSSESSING ANTI-CACHEXIC, ANTI-TUMOUR PROPERTIES AND REDUCING ENDOGENOUS INTOXICATION LEVEL | 2015 |
|
RU2601406C1 |
METHOD FOR ENHANCING ANTIMETASTATIC ACTION OF CISPLATIN AND REDUCING ITS SIDE EFFECT ON HAEMOSTASIS SYSTEM | 2023 |
|
RU2825825C1 |
METHOD OF TREATMENT OF MALIGNANT TUMORS AND COMPOSITION FOR ITS REALIZATION | 1993 |
|
RU2074736C1 |
AGENT POSSESSING ANTI-INFLAMMATORY, ANTIPYRETIC AND ANTIMICROBIAL ACTION | 2013 |
|
RU2535155C1 |
Authors
Dates
2020-10-13—Published
2020-03-04—Filed